ASCO 2017: Whole blood androgen receptor variant expression and overall survival in metastatic castrate resistant prostate cancer

Chicago, IL ( The detection of full length androgen receptor (AR-FL) or AR variants (AR-Vs) in blood and association with outcomes in metastatic castrate-resistant prostate cancer (mCRPC) is unknown. Dr. Karthik Giridhar presented a study comparing whole blood mRNA expression of AR-FL and AR-Vs to circulating tumor cells (CTCs) for predicting overall survival (OS) and time to treatment failure (TTF). 

Overall, 92 men with mCRPC were enrolled in the PROMOTE study. After obtaining a pretreatment first blood test and metastatic site biopsy, patients were treated with Abiraterone and prednisone. Peripheral blood gene expression sequencing was available for 53 men. The authors also isolated RNA from whole blood collected in PAXgene RNA tubes. Whole transcriptome sequencing (RNAseq) was performed on blood samples and paired biopsies to detect AR-FL, ARV1, ARV3, ARV7, ARV8, AR12, ARV14, and ARV45. Reads were aligned to the GRCh38 reference genome with the spliced-alignment TopHat2 package. Lastly, CTCs were determined using the CELLSEARCH assay.

Median age was 75 (70-79) with a median PSA of 11.8 (5.4-41) at time of CRPC. The median follow-up was 2.85 years, (range 0.27-3.45), and the median CTC count was 3 (range 0-372); 34/53 men were deceased. Blood based AR-FL or AR-Vs were detected in 50/53 patients with following distribution: AR-FL (41/53), ARV3 (9/53), ARV45 (8/53), ARV12 (4/53), ARV14 (4/53), ARV7 (2/53), and ARV8 (2/53). Whole blood AR-FL transcripts were highly correlated to paired bone biopsy (r2= 0.76). Elevated transcripts of either ARV12 or ARV14 were associated with decreased overall survival (OS) [hazard ratio (HR) 3.46, p = 0.006]. CTC count ≥5 was associated with poorer OS [HR 3.42, p = 0.02] and shorter TTF [HR 3.52, p = < 0.001]. Adjusting for CTC counts, in a multivariable model, blood AR12 and ARR14 expression was associated with poor OS [HR = 6.33, p = 0.009]. AR12 and CTCs trended toward improved AUC compared to CTC alone (0.78 vs 0.71, p = 0.07). 

AR-FL and AR-Vs are detectable in whole blood and are highly correlated with metastatic bone AR-FL expression. AR-Vs may add to prognostication in mCRPC and further validation is needed, with testing expanded beyond ARV7.

Presented by: Karthik Giridhar, MD, Mayo Clinic, Rochester, MN

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Twitter: @GoldbergHanan

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 - Chicago, Illinois, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.